Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

Phase 1

Completed

Conditions: Breast Cancer
Colorectal Cancer
Lung Cancer
Renal Cancer
Hepatocellular Cancer
Pancreatic Cancer

Interventions: Drug: NIS793
Drug: PDR001

First Posted Date: 2016-10-27

Last Posted Date: 2022-01-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 120

Registration Number: NCT02947165

Locations: 🇺🇸
Sarah Cannon Research Institute SC, Nashville, Tennessee, United States
🇺🇸
Huntsman Cancer Institute SC, Salt Lake City, Utah, United States
🇨🇳
Novartis Investigative Site, Taipei, Taiwan

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Ribociclib
Drug: Letrozole
Drug: Goserelin
Drug: Leuprolide

First Posted Date: 2016-10-21

Last Posted Date: 2023-10-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3246

Registration Number: NCT02941926

Locations: 🇺🇸
Ventura County Hematology and Oncology, Oxnard, California, United States
🇺🇸
Mid Florida Hematology and Onc Ctr, Orange, Florida, United States
🇺🇸
Hope Cancer Center of East Texas, Tyler, Texas, United States

and more 69 locations

Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients

Phase 2

Terminated

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: QCC374

First Posted Date: 2016-10-20

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 5

Registration Number: NCT02939599

Locations: 🇬🇧
Novartis Investigative Site, Cambridge, Cambridgeshire, United Kingdom

A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Phase 1

Active, not recruiting

Conditions: Triple Negative Breast Cancer
Chordoma and Alveolar Soft Part Sarcoma
Advanced Solid Tumors

Interventions: Drug: FAZ053
Drug: PDR001

First Posted Date: 2016-10-18

Last Posted Date: 2024-11-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 154

Registration Number: NCT02936102

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Ctr, New York, New York, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇨🇳
Novartis Investigative Site, Taipei, Taiwan

Ribociclib (LEE011) Rollover Study for Continued Access

Phase 2

Recruiting

Conditions: Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies

Interventions: Drug: LEE011

First Posted Date: 2016-10-17

Last Posted Date: 2024-04-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 50

Registration Number: NCT02934568

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
🇺🇸
University Of Alabama At Birmingham, Birmingham, Alabama, United States
🇺🇸
Dana Farber Cancer Institute Main Site, Boston, Massachusetts, United States

and more 3 locations

Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients

Phase 2

Terminated

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: QCC374
Drug: Placebo Matching

First Posted Date: 2016-10-07

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 8

Registration Number: NCT02927366

Locations: 🇬🇧
Novartis Investigative Site, Cambridge, Cambridgeshire, United Kingdom

A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.

Phase 1

Completed

Conditions: cMET Dysegulation Advanced Solid Tumors

Interventions: Drug: INC280

First Posted Date: 2016-10-05

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT02925104

Locations: 🇺🇸
Indiana University Simon Cancer Center SC, Indianapolis, Indiana, United States
🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

Phase 3

Completed

Conditions: Acute Myocardial Infarction

Interventions: Drug: LCZ696 (sacubitril/valsartan)
Drug: Ramipril
Drug: Placebo of ramipril
Drug: Placebo of LCZ696
Drug: Placebo of valsartan
Drug: Valsartan

First Posted Date: 2016-10-05

Last Posted Date: 2023-06-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 5669

Registration Number: NCT02924727

Locations: 🇬🇧
Novartis Investigative Site, Worcester, United Kingdom

Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation

Phase 3

Completed

Conditions: Corticosteroid Refractory Acute Graft vs Host Disease

Interventions: Drug: Ruxolitinib (RUX)
Drug: Best Available Therapy (BAT)

First Posted Date: 2016-09-23

Last Posted Date: 2023-02-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 310

Registration Number: NCT02913261

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

Phase 2

Terminated

Conditions: Non-alcoholic Steatohepatitis NASH

Interventions: Drug: LMB763
Drug: Placebo

First Posted Date: 2016-09-23

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 122

Registration Number: NCT02913105

Locations: 🇬🇧
Novartis Investigative Site, Portsmouth, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy